Reputation for Excellence Drives Sale of 21 More ETDs by Implant Sciences

WILMINGTON, Mass., Feb. 11, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced its latest sale of 21 explosives trace detectors (ETD) including 11 QS-B220 desktop and 10 QS-H150 handheld units. Based on the reputation of Implant Sciences' ETDs for reliability and performance in critical infrastructure protection settings, the Company has made significant market penetration for this application. Sales of systems deployed to protect 'hard target' infrastructure have increased by 100% in the past year, with a 63% compound annual growth rate (CAGR) since 2009. 

"Implant Sciences has been selling trace detection equipment in Asia since 2004. Our products have earned an excellent reputation for performance and reliability," stated Joe Laskey, Implant Sciences' General Manager for the Asia region. "For many of our customers in the region, 'Implant Sciences' is synonymous with 'security'."

"These units will be deployed to protect infrastructure and buildings in Asia. The combination of our handheld QS-H150 and our desktop QS-B220 offers the flexibility to handle a broad range of screening needs. Everything from vehicles and people to packages and equipment entering a site can be tested quickly and cost-effectively at either checkpoint or field locations," added Implant Sciences' VP of Sales and Marketing, Darryl Jones.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and  the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700       

or

Investor Contact:
Laurel Moody
646-810-0608

SOURCE Implant Sciences Corporation